CClinicalTrials.gg
Not yet recruitingNCT07821671Updated Sep 16, 2026

Improving TelePrEP Initiation and Retention Outcomes in the US: The MISTR+ Study

An interventional study of No Marginal Cost Interventions and Low-Marginal Cost Interventions in Human Immunodeficiency Virus, sponsored by Emory University. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-16.

Sponsored by Emory University · Not applicable, Interventional, and Health services research

Phase
Not applicable
Study type
Interventional
Enrollment
223,165
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

This study uses a rapid randomized controlled trial (RCT) design to examine HIV pre-exposure prophylaxis (PrEP) delivered through telehealth. This study will develop a knowledge base of small, effective changes to digital messaging and website design to improve telemedicine PrEP (telePrEP) provision for MISTR users in the United States.

Read the detailed description

HIV pre-exposure prophylaxis (PrEP) is highly effective but levels of initiation are suboptimal. Low retention in PrEP care limits the impact of PrEP, and discontinuation is frequent among persons at continued high risk for HIV transmission. Telemedicine PrEP (telePrEP) is a promising mechanism for delivery to address challenges in PrEP initiation, retention, and reengagement.

This trial is framed by a learning healthcare systems (LHS) model, introduced by the Institute of Medicine over a decade ago. The LHS aims to establish a reciprocal cycle among clinical practice, data, and knowledge to continuously improve healthcare quality. LHS continuously generates and tests new interventions, learning what works best through systematic assessments such as clinical trials, quasi-experiments, and bringing successful interventions to scale.

Nudge-based interventions in healthcare have promising early results. Nudges are components of "choice architecture" that alter behavior in a predictable way and are easy to achieve. Nudges, such as text messages and other electronic prompts, have demonstrated impact on areas ranging from patient continuation in medical care and medication adherence to physician prescribing behavior. Nudges can be assessed through rapid randomized controlled trial (RCT) testing the original version against a single change (A/B testing). This approach is optimal to improve telehealth delivery because interventions can have no or very low costs and easily be tested with a rapid RCT approach.

To capitalize on the promise of telePrEP by improving initiation, retention, and re-engagement, the researchers propose an implementation project that will leverage rapid RCT to optimize PrEP delivery for 1/5th of all PrEP users in the United States. Emory University has established a collaboration and data use agreement with the largest national telePrEP provider, MISTR, which provides services at no out-of-pocket cost to all users. The Emory-MISTR agreement allows for transmission of limited datasets, which will allow Emory to receive all data needed for the trial. MISTR also has agreed to modify their platform to test the proposed interventions and scale ones that are efficacious.

Aim 1 will develop an evidence base to inform selection of a set of intervention candidates. Aim 2 will be rapid RCT which compare interventions that entail no marginal cost per additional user to the standard of care MISTR service. Aim 3 will be rapid RCT to assess the impact of several low-marginal cost interventions on PrEP initiation, retention, and re-engagement.

The interventions in this study are all designed to be small improvements to digital messaging and website design, based on the current MISTR system. This study does not involve collecting any additional information or data on MISTR users beyond what is already collected as part of their standard care in terms of intake surveys, website use data, and PrEP prescribing data. There is no active recruitment of participants and no direct contact with participants for the study.

02

Conditions studied

  • Human Immunodeficiency Virus

Keywords

  • PrEP
  • Pre-exposure Prophylaxis
  • Telemedicine
03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Adults aged >= 18 years
  • Individuals who use MISTR services
  • Reside in the United States

Exclusion criteria

Exclusion Criteria:

  • Individuals who do not use MISTR services
  • Individuals who do not reside in the United States
04

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
223,165 participants (estimated)

Study arms

  • Experimental
    Intervention Condition

    Individuals using MISTR services receiving an intervention condition.

    Behavioral: No Marginal Cost Interventions · Behavioral: Low-Marginal Cost Interventions

  • Active comparator
    Control Condition

    Individuals using MISTR services receiving the standard of care.

    Behavioral: Standard of Care

Interventions

  • BehavioralNo Marginal Cost Interventions

    The exact intervention types will be determined based on Aim 1 data analyses that seek to identify the areas that could most benefit from intervention. Possible interventions to be tested include message content, message format, message time of day, and website design.

  • BehavioralLow-Marginal Cost Interventions

    The exact intervention types will be determined based on Aim 1 data analyses that seek to identify the areas that could most benefit from intervention. Possible interventions to be tested include warm handoffs, personalized messages, and enhanced remote laboratory testing.

  • BehavioralStandard of Care

    MISTR users receive the current standard of care. The standard of care will be updated as impactful interventions are identified.

05

What researchers measure

Primary outcomes

  1. Number of Participants Initiating PrEP

    PrEP initiation is defined as a participant receiving a mailed PrEP prescription from MISTR within two months of registration.

    Time frame: Through the intervention period (2 to 4 months)

  2. Number of Participants with PrEP Retention

    PrEP retention in care is defined as a successfully renewed and mailed PrEP prescription within plus or minus one month of the scheduled date for renewal.

    Time frame: Through the intervention period (2 to 4 months)

  3. Number of Participants with PrEP Re-Engagement

    PrEP re-engagement is defined as receiving a mailed PrEP prescription within two months of a re-engagement intervention being initiated.

    Time frame: Through the intervention period (2 to 4 months)

06

Study locations

1 site
  • Emory University Rollins School of Public Health
    Atlanta, Georgia 30322, United States
07

References and documents

Individual participant data

Plan to share: No — The data are owned by a private company (MISTR). The researchers are accessing the data through a data use agreement that does not allow for sharing of individual level data. Study findings in aggregate form will be shared though publications and presentations.

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT07821671
Lead sponsor
Emory University
Collaborators
National Institute of Allergy and Infectious Diseases (NIAID)
Responsible party
Aaron Siegler (Professor, Emory University) — Principal investigator
First posted
Sep 16, 2026
Start date
Mar 1, 2027 (estimated)
Primary completion
May 31, 2031 (estimated)
Completion
May 31, 2031 (estimated)
Last update
Sep 16, 2026

Study contacts

Aaron Siegler, PhD
Contact
asiegle@emory.edu
404-712-9733
Rebecca Moges-Banks, MPH
Contact
Rebecca.moges-banks@emory.edu
Aaron Siegler, PhD
principal investigator · Emory University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion